USH819H - Palladium-109 labeled anti-melanoma monoclonal antibodies - Google Patents
Palladium-109 labeled anti-melanoma monoclonal antibodies Download PDFInfo
- Publication number
- USH819H USH819H US06/605,439 US60543984A USH819H US H819 H USH819 H US H819H US 60543984 A US60543984 A US 60543984A US H819 H USH819 H US H819H
- Authority
- US
- United States
- Prior art keywords
- palladium
- melanoma
- antibody
- monoclonal antibodies
- labeled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- KDLHZDBZIXYQEI-AKLPVKDBSA-N palladium-109 Chemical compound [109Pd] KDLHZDBZIXYQEI-AKLPVKDBSA-N 0.000 title claims abstract description 27
- 230000003127 anti-melanomic effect Effects 0.000 title abstract description 5
- 201000001441 melanoma Diseases 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims description 13
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical group OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 8
- 239000013522 chelant Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 229960003330 pentetic acid Drugs 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 3
- 229940121896 radiopharmaceutical Drugs 0.000 claims description 3
- 239000012217 radiopharmaceutical Substances 0.000 claims description 3
- 230000002799 radiopharmaceutical effect Effects 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000003439 radiotherapeutic effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 18
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 12
- 239000000463 material Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000013459 approach Methods 0.000 description 6
- 150000008064 anhydrides Chemical class 0.000 description 5
- 239000008351 acetate buffer Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- -1 cyclic anhydride Chemical class 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000011717 athymic nude mouse Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- DIGMLMRBDDSXMD-MSOXLDFBSA-N dnc005791 Chemical compound N=1N=NN(CCCCC(=O)NCCCOCCOCCOCCCNC(=O)[C@H](CS(O)(=O)=O)NC(=O)[C@H](CS(O)(=O)=O)NC(=O)[C@H](CS(O)(=O)=O)NC(=O)[C@H](CS(O)(=O)=O)NC(=O)CC[C@H](NC(=O)CN(CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)CC(O)=O)C(=O)N[C@@H](CS(O)(=O)=O)C(=O)N[C@@H](CS(O)(=O)=O)C(=O)N[C@@H](CS(O)(=O)=O)C(=O)N[C@@H](CS(O)(=O)=O)C(=O)NCCCOCCOCCOCCCNC(=O)CCCCN2C(=NN=N2)C(C)(C)CCCCOC=2N=C(C=C(C=2)C=2C=CC=CC=2)C=2C=CC=CC=2)C=1C(C)(C)CCCCOC(N=1)=CC(C=2C=CC=CC=2)=CC=1C1=CC=CC=C1 DIGMLMRBDDSXMD-MSOXLDFBSA-N 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- KDLHZDBZIXYQEI-NJFSPNSNSA-N palladium-108 Chemical compound [108Pd] KDLHZDBZIXYQEI-NJFSPNSNSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RAZLJUXJEOEYAM-UHFFFAOYSA-N 2-[bis[2-(2,6-dioxomorpholin-4-yl)ethyl]azaniumyl]acetate Chemical compound C1C(=O)OC(=O)CN1CCN(CC(=O)O)CCN1CC(=O)OC(=O)C1 RAZLJUXJEOEYAM-UHFFFAOYSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- JGUQDUKBUKFFRO-CIIODKQPSA-N dimethylglyoxime Chemical compound O/N=C(/C)\C(\C)=N\O JGUQDUKBUKFFRO-CIIODKQPSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Definitions
- the Figure shows the in vitro binding of palladium-109 labeled anti-Human High Molecular Weight Melanoma Associated Antigen Monoclonal Antibody 225.28S to human COLO 38 melanoma cells and to lymphoma cells in times culture.
- the present invention consists of new radiolabeled monoclonal antibodies, the method of preparing these material, and there use in the radiotherapy of melanoma. More specifically the present invention is directed to the use of anti-melanoma monoclonal antibodies which have been chelate-conjugated and radiolabeled as carriers of radioactivity to the site of a tumor for the purpose of inducing tumor therapy.
- the radionuclide employed is palladium-109, which is a predominantly beta-emitting radionuclide with a half-life of 13.4 hours, a beta emission of 1.028 MeV maximum, and a scatter area of 2 mm.
- Palladium-109 is available in meaningful quantities and can be obtained in almost carrier-free form, a necessity for human application.
- the palladium-109 that has been used in the experimental work discussed herein has been produced at the High Flux Beam Reactor (HFBR) at Brookhaven National Laboratory. This material exhibits a specific activity at the end of bombardment of approximately 1 Curie per milligram.
- the palladium-109 radionuclide will be produced at the Brookhaven Linac Isotope Production Facility (BLIP).
- BLIP Brookhaven Linac Isotope Production Facility
- the material that will be produced at the BLIP will exhibit higher specific activity and will be essentially carrier free.
- the bifunctional chelate employed is diethylenetriamine pentaacetic acid (DTPA) which can be coupled to the monoclonal antibody using several different synthetic approaches.
- DTPA diethylenetriamine pentaacetic acid
- One approach involves the use of mixed anhydrides and this synthetic method has been reported by Krejcarek, et al. in a paper entitled “Covalent Attachment of Chelating Groups to Macromolecules", Biochemical and Biophysical Research Communications, 77 581-585 (1977).
- the second approach to linking the DTPA to the monoclonal antibody is the cyclic anhydride approach reported by E. Kehuan, et al., Journal of Pharmacological Science, 64, 704-706 (1975), and by Hnatowich, et al.
- the monoclonal antibodies employed in the present invention are a family of antibodies to human high molecular weight melanoma associated antigens. This family of monoclonal antibodies contains six distinct antibodies designated by the following identifying numbers: 138.13S, 225.28S, 653.40S, 763.24T, 376.96S, and 465.12S. Several of these antibodies recognize one determinant while others recognize more than one. The high degree of heterogeneity exhibited by the tumor can be overcome to some extent by using a combination of several of the above monoclonal antibodies which will then recognize various antigens or determinants. The preparation of the monoclonal antibody 653.40S is reported by Ferrone, et al.
- the palladium-109 labeled monclonal antibodies of the present invention are useful in the therapeutic treatment of tumors.
- the mammalian subject in need of such therapeutic treatment may be treated with the palladium-109 labeled material by administration of this material through intravenous infusion.
- the palladium-109 labeled monoclonal antibodies may be infused very slowly, preferably over a period of about one hour, as pure material or they may be diluted with saline or dextrose for infusion.
- the administration regimen to be followed will depend on the individual patient. In general, about 150 millicuries bound to 100 ⁇ g-2 mg of the antibody should provide the therapeutic dose for most human patients.
- the palladium-109 labeled monoclonal antibodies will upon administration seek out the site of the melanoma and deliver to the tumor the prescribed dose of radiation.
- These radiopharmaceutical compositions will seek out both the primary and secondary melanoma sites, that is the primary site of the tumor and any secondary sites resulting from metastasis.
- Hybridomas were constructed with the murine myeloma cell line Sp2/0-Ag-14 and splenocytes from mice immunized with the melanoma cell line M21 as described in Ferrone, et al., Transplantation Proceedings, 12, 380-383 (1980).
- the hybridomas secreting the monoclonal antibody 225.28S have been subcloned and propagated in vitro and in vivo.
- the monoclonal antibody 225.28S is cell membrane reactive.
- the monoclonal antibody 465.12S was also prepared. This monoclonal antibody is cytoplasm reactive. Both the 225.28S and 485.12S monoclonal antibodies are of the IgG2a subclass and were purified from mouse ascites fluid by adsorption/elution from protein A Sepharose 4B (purchased from Pharmacia, Piscataway, N.J.).
- the monoclonal antibody 653.40S was also prepared. This monoclonal antibody falls into the IgGI subclass.
- DTPA anhydride was added to the antibody at a pH of 7.0 (HEPES, 0.05M) and incubated for 30 minutes at room temperature.
- the antibody concentration was kept between 0.2 and 1.5 milligrams per milliliter, and the ratio of anhydride to antibody was either 1:1 or 10:1.
- the resulting mixture was dialyzed against two one-liter batches of 0.05M HEPES (pH 7.0) at 4° C. for two days.
- the mixed anhydride method a 300 to 2000 fold excess of the anhydride was added to the antibody at a pH of 7 to 8 (0.1M NaHCO 3 ) and incubation carried out at 4° C. overnight.
- the protein concentration varied between 0.2 and 1.5 milligrams per milliliter.
- the mixture was then dialyzed against two one-liter batches of a 0.1M acetate buffer, pH 5.0 (or with 0.1M glycine/HCl buffer at pH 3.5) at 4° C. for two days.
- Palladium-109 chloride was prepared by bombarding palladium-108 chloride in a sealed quartz ampule in the Brookhaven High Flux Beam Reactor (8 ⁇ 10 14 n s -1 cm -2 ) for 24 hours. Typically, approximately two milligrams of palladium as palladium-108 chloride provided over two Curies of palladium-109 at the end of bombardment. The material was dissolved in either 2.0 milliliters DMSO or in 1 ml of a 0.1M pH5 acetate buffer by gentle heating and stirring.
- This column method provided an effective separation of the desired palladium-109 labeled monoclonal antibody DTPA conjugate from unwanted impurities found in the preparation.
- the yield varied between 6 and 10 percent depending on the amount of palladium-109 used and the amount of the monoclonal antibody DTPA solution.
- the specific activity of these preparations was 0.6-1.0 ⁇ Ci of palladium-109/ ⁇ g protein.
- the labeling yields and the specific activity of the preparations can be increased much further by employing carrier-free palladium-109.
- Tumor Cell Lines Human melanoma cells (COLO-38) were cultured in RPMI 1640 medium with L-glutamycin. Solid tumors were produced in athymic nude mice (Swiss/Webster,nu/nu) by injection of 10 7 melanoma cells in the flank. The tumors were allowed to reach a size of approximately 5 mm in diameter prior to experimentation.
- FIG. 1 demonstrates that Pd-109-MoAB 225.28S achieved significantly (P ⁇ 0.001) higher melanoma cell binding in tissue culture (41.3% in the plateau region) than with control lymphoma cells (3.1%).
- Decreased liver and renal uptake and enhanced tumor to background ratios can be achieved by using carrier free palladium-109, increasing the binding efficiency (under different conditions and using other chelating agents) of palladium-109 to antibody, and by using antibody fragments labeled with palladium-109.
Abstract
Palladium-109, a beta-emitting radionuclide, when chelated to anti-melanoma monoclonal antibody demonstrates high uptake in melanoma and thus is useful for tumor therapy.
Description
The U. S. Government has rights in this invention pursuant to Contract Number DE-AC02-76CH00016, between the U.S. Department of Energy and Associated Universities Inc.
Recently, monoclonal antibodies labeled with the radionuclide iodine-131 have been used for the detection of tumors. Goldenberg reported the imaging of tumors using monoclonal antibodies [Journal of Nuclear Medicine, 24, 360-362 (1983)] while Larson, et al. reported melanoma imaging using iodine-131 labeled monoclonal antibodies [Journal of Nuclear Medicine, 24, 123-129 (1983)]. One of the problems that has been encountered with such radionuclide labeled monoclonal antibodies has been that the labeling inactivates the antibody because the radionuclide attaches at or near the antigen-binding sites. One approach to overcoming this problem is to employ bi-functional chelates that are capable of covalently binding to the antibody and also complexing with a metallic radionuclide. Krejcarek, et al. discuss the covalent attachment of chelating groups to macromolecules, [Biochemical and Biophysics Research Communications, 77, 581-585 (1977)].
The Figure shows the in vitro binding of palladium-109 labeled anti-Human High Molecular Weight Melanoma Associated Antigen Monoclonal Antibody 225.28S to human COLO 38 melanoma cells and to lymphoma cells in times culture.
The present invention consists of new radiolabeled monoclonal antibodies, the method of preparing these material, and there use in the radiotherapy of melanoma. More specifically the present invention is directed to the use of anti-melanoma monoclonal antibodies which have been chelate-conjugated and radiolabeled as carriers of radioactivity to the site of a tumor for the purpose of inducing tumor therapy.
The radionuclide employed is palladium-109, which is a predominantly beta-emitting radionuclide with a half-life of 13.4 hours, a beta emission of 1.028 MeV maximum, and a scatter area of 2 mm. Palladium-109 is available in meaningful quantities and can be obtained in almost carrier-free form, a necessity for human application. The palladium-109 that has been used in the experimental work discussed herein has been produced at the High Flux Beam Reactor (HFBR) at Brookhaven National Laboratory. This material exhibits a specific activity at the end of bombardment of approximately 1 Curie per milligram. For future human application, it is intended that the palladium-109 radionuclide will be produced at the Brookhaven Linac Isotope Production Facility (BLIP). The material that will be produced at the BLIP will exhibit higher specific activity and will be essentially carrier free.
The bifunctional chelate employed is diethylenetriamine pentaacetic acid (DTPA) which can be coupled to the monoclonal antibody using several different synthetic approaches. One approach involves the use of mixed anhydrides and this synthetic method has been reported by Krejcarek, et al. in a paper entitled "Covalent Attachment of Chelating Groups to Macromolecules", Biochemical and Biophysical Research Communications, 77 581-585 (1977). The second approach to linking the DTPA to the monoclonal antibody is the cyclic anhydride approach reported by E. Kehuan, et al., Journal of Pharmacological Science, 64, 704-706 (1975), and by Hnatowich, et al. in "Radioactive Labeling of Antibody: A Simple and Efficient Method", Science, 220, 613-615 (1983). The cyclic anhydride approach for the preparation of the chelate-conjugated monoclonal antibodies of the present invention is preferred. Other chelating agents may be used in place of the DTPA. For example, several polyamine-carboxylate compounds, 8-hydroxy quinoline and its derivatives, dimethylglyoxime, and desferrioxamine, are also suitable chelating agents for conjugation to the monoclonal antibody for attaching the metallic radionuclide palladium-109.
The monoclonal antibodies employed in the present invention are a family of antibodies to human high molecular weight melanoma associated antigens. This family of monoclonal antibodies contains six distinct antibodies designated by the following identifying numbers: 138.13S, 225.28S, 653.40S, 763.24T, 376.96S, and 465.12S. Several of these antibodies recognize one determinant while others recognize more than one. The high degree of heterogeneity exhibited by the tumor can be overcome to some extent by using a combination of several of the above monoclonal antibodies which will then recognize various antigens or determinants. The preparation of the monoclonal antibody 653.40S is reported by Ferrone, et al. in the Journal of the National Cancer Institute, 67, 591-601 (1981). The preparation of the monclonal antibodies 225.28S and 465.12S is reported by Ferrone, et al. in the International Journal of Cancer, 28, 293-300 (1981). The other members of this monoclonal antibody family are prepared following the procedures and purification methods reported in both of the cited Ferrone, et al. papers.
It has been discovered that palladium-109 when chelated to anti-melanoma monoclonal antibodies demonstrates high uptake in human melanoma. Therefore, these novel palladium-109 labeled, chelate conjugated monoclonal antibodies are therapeutically useful for tumor therapy. It is recognized that the tumor therapy attributes of the material might also be substantially enhanced by using antibody fragments to increase blood clearance, decrease bone marrow toxicity, and to decrease normal tissue uptake.
The palladium-109 labeled monclonal antibodies of the present invention are useful in the therapeutic treatment of tumors. For this purpose, the mammalian subject in need of such therapeutic treatment may be treated with the palladium-109 labeled material by administration of this material through intravenous infusion. The palladium-109 labeled monoclonal antibodies may be infused very slowly, preferably over a period of about one hour, as pure material or they may be diluted with saline or dextrose for infusion. The administration regimen to be followed will depend on the individual patient. In general, about 150 millicuries bound to 100 μg-2 mg of the antibody should provide the therapeutic dose for most human patients. The palladium-109 labeled monoclonal antibodies will upon administration seek out the site of the melanoma and deliver to the tumor the prescribed dose of radiation. These radiopharmaceutical compositions will seek out both the primary and secondary melanoma sites, that is the primary site of the tumor and any secondary sites resulting from metastasis.
Hybridomas were constructed with the murine myeloma cell line Sp2/0-Ag-14 and splenocytes from mice immunized with the melanoma cell line M21 as described in Ferrone, et al., Transplantation Proceedings, 12, 380-383 (1980). The hybridomas secreting the monoclonal antibody 225.28S have been subcloned and propagated in vitro and in vivo. The monoclonal antibody 225.28S is cell membrane reactive.
Following exactly the same procedure as described above, the monoclonal antibody 465.12S was also prepared. This monoclonal antibody is cytoplasm reactive. Both the 225.28S and 485.12S monoclonal antibodies are of the IgG2a subclass and were purified from mouse ascites fluid by adsorption/elution from protein A Sepharose 4B (purchased from Pharmacia, Piscataway, N.J.).
Following the specific procedures described above, the monoclonal antibody 653.40S was also prepared. This monoclonal antibody falls into the IgGI subclass.
Two methods were used for conjugating DTPA to the antibody; the mixed anhydride method and the cyclic anhydride method. In the latter method, the DTPA anhydride was added to the antibody at a pH of 7.0 (HEPES, 0.05M) and incubated for 30 minutes at room temperature. The antibody concentration was kept between 0.2 and 1.5 milligrams per milliliter, and the ratio of anhydride to antibody was either 1:1 or 10:1. The resulting mixture was dialyzed against two one-liter batches of 0.05M HEPES (pH 7.0) at 4° C. for two days. In the mixed anhydride method, a 300 to 2000 fold excess of the anhydride was added to the antibody at a pH of 7 to 8 (0.1M NaHCO3) and incubation carried out at 4° C. overnight. The protein concentration varied between 0.2 and 1.5 milligrams per milliliter. The mixture was then dialyzed against two one-liter batches of a 0.1M acetate buffer, pH 5.0 (or with 0.1M glycine/HCl buffer at pH 3.5) at 4° C. for two days.
Antibody With Palladium-109
Palladium-109 chloride was prepared by bombarding palladium-108 chloride in a sealed quartz ampule in the Brookhaven High Flux Beam Reactor (8×1014 n s-1 cm-2) for 24 hours. Typically, approximately two milligrams of palladium as palladium-108 chloride provided over two Curies of palladium-109 at the end of bombardment. The material was dissolved in either 2.0 milliliters DMSO or in 1 ml of a 0.1M pH5 acetate buffer by gentle heating and stirring. An aliquot of this solution (10-20 μl) was transferred into a 10 ml multi-injection bottle containing 1 ml of a pH 5.0, 0.1M acetate buffer and 0.3 ml of the monoclonal antibody DTPA conjugate (1.43 mg/ml in acetate buffer). The mixture was incubated at 37° for two hours and then applied onto a 0.9×100 cm Sephadex G-150 column for purification. The eluting buffer consisted of 0.05 M HEPES, pH 7.0. The radioactivity of the fraction was assayed using a dose calibrator and the appropriate fractions combined and concentrated to reduce the volume. This column method provided an effective separation of the desired palladium-109 labeled monoclonal antibody DTPA conjugate from unwanted impurities found in the preparation. The yield varied between 6 and 10 percent depending on the amount of palladium-109 used and the amount of the monoclonal antibody DTPA solution. The specific activity of these preparations was 0.6-1.0 μCi of palladium-109/ μg protein. The labeling yields and the specific activity of the preparations can be increased much further by employing carrier-free palladium-109.
In Vitro Binding Assay: To determine the melanoma binding affinity of the Pd--09 labeled anti-melanoma monoclonal antibody, cultured COLO-38 human melanoma cells were incubated for one hour at room temperature with the radiolabeled antibody. Cultured human lymphoma cells incubated in a similar manner were used as a control. The cells were washed three times and the binding of antibody to cells was determined in triplicate at antibody dilutions ranging from 1:1 to 1:128.
TABLE 1 ______________________________________ Percent of Administered Pd-109 MoAb 225.28s Per Gram Tissue Hours Post Injection 13 24 48 ______________________________________ Blood 0.50 ± 0.03 0.51 ± 0.04 0.30 ± 0.04 Tumor 19.99 ± 0.54 19.51 ± 1.46 18.51 ± 2.11 Lung 1.46 ± 0.07 0.94 ± 0.12 0.64 ± 0.05 Liver 5.04 ± 0.41 4.54 ± 0.44 4.26 ± 0.18 Spleen 2.69 ± 0.16 3.15 ± 0.40 3.01 ± 0.11 Kidney 13.67 ± 0.46 11.15 ± 1.50 10.05 ± 1.16 Muscle 0.51 ± 0.05 0.55 ± 0.29 0.32 ± 0.07 Bone 1.35 ± 0.08 1.48 ± 0.18 1.31 ± 0.14 ______________________________________
Tumor Cell Lines: Human melanoma cells (COLO-38) were cultured in RPMI 1640 medium with L-glutamycin. Solid tumors were produced in athymic nude mice (Swiss/Webster,nu/nu) by injection of 107 melanoma cells in the flank. The tumors were allowed to reach a size of approximately 5 mm in diameter prior to experimentation.
In Vitro Binding of Pd-109-MoAB 225.28S to Melanoma: FIG. 1 demonstrates that Pd-109-MoAB 225.28S achieved significantly (P <0.001) higher melanoma cell binding in tissue culture (41.3% in the plateau region) than with control lymphoma cells (3.1%).
Three groups of athymic nude mice bearing COLO 38 human melanoma tumor (n=3-6/group) were injected with 10 μCi of Pd-109-MoAb 225.28S and sacrificed 13,24 and 48 hours later, respectively, for determination of radioactivity (% injected dose/g). As shown in Table 1, the concentration of Pd-109 MoAb 25.28S in melanoma at different periods after administration of radioactivity was uniformly higher (P <0.001) than achieved in other tissues.
Decreased liver and renal uptake and enhanced tumor to background ratios can be achieved by using carrier free palladium-109, increasing the binding efficiency (under different conditions and using other chelating agents) of palladium-109 to antibody, and by using antibody fragments labeled with palladium-109.
Claims (4)
1. A radiopharmaceutical composition consisting of the monoclonal antibodies to human high molecular weight melanoma associated antigens, or fragments of said antibodies which are chelate-conjugated and labeled with palladium-109.
2. The composition of claim 1 wherein the monoclonal antibody is MoAb 225.28S.
3. The composition of claim 6 wherein the chelate component is diethylenetriaminepentaacetic acid (DTPA).
4. A radiotherapeutic method of treating melanoma by the intravenous infusion of a radiopharmaceutical composition consisting of an antibody to human high molecular weight melanoma associated antigens, or a fragment of said antibody, which is chelate-conjugated and labeled with palladium-109.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/605,439 USH819H (en) | 1984-04-30 | 1984-04-30 | Palladium-109 labeled anti-melanoma monoclonal antibodies |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/605,439 USH819H (en) | 1984-04-30 | 1984-04-30 | Palladium-109 labeled anti-melanoma monoclonal antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
USH819H true USH819H (en) | 1990-09-04 |
Family
ID=24423663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/605,439 Abandoned USH819H (en) | 1984-04-30 | 1984-04-30 | Palladium-109 labeled anti-melanoma monoclonal antibodies |
Country Status (1)
Country | Link |
---|---|
US (1) | USH819H (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744119A (en) * | 1993-05-11 | 1998-04-28 | Sterling Winthrop | Preparation of a radioconjugate formulation |
US6168946B1 (en) * | 1990-03-22 | 2001-01-02 | Sloan-Kettering Institute For Cancer Research | gp75 as a tumor vaccine for melanoma |
WO2005000349A2 (en) * | 2003-06-23 | 2005-01-06 | Biolife Science Forschungs- Und Entwicklungsgesellschaft M.B.H. | Passive immune therapy against malignant melanoma |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
US4452774A (en) | 1982-04-30 | 1984-06-05 | President And Fellows Of Harvard College | Isonitrile radionuclide complexes for labelling and imaging agents |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4500508A (en) | 1983-05-03 | 1985-02-19 | The United States Of America As Represented By The United States Department Of Energy | Radionuclide labeled lymphocytes for therapeutic use |
-
1984
- 1984-04-30 US US06/605,439 patent/USH819H/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
US4452774A (en) | 1982-04-30 | 1984-06-05 | President And Fellows Of Harvard College | Isonitrile radionuclide complexes for labelling and imaging agents |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4500508A (en) | 1983-05-03 | 1985-02-19 | The United States Of America As Represented By The United States Department Of Energy | Radionuclide labeled lymphocytes for therapeutic use |
Non-Patent Citations (17)
Title |
---|
CRC Handbook Series in Clinical Laboratory Science, Section A: Nuclear Meine, vol. II, CRC Press, Inc., Boca Raton, Fla., (1982), p. 147. |
Fawwaz et al., J. Nucl. Med., 24(5), p. 78, (May 1983). |
Fawwaz et al., J. Nucl. Med., 25:796-9, (1984). |
Goldenberg, J. Nucl. Med., 24(4), 360-62, (1983). |
Halpern et al., J. Nucl. Med., 23, p. 8, (May, 1982). |
Hnatowich et al., Int. J. Appl. Rad. Isotopes, 33, 327-32, (1983). |
Imai et al., Chemical Abstracts, 99, (1983), #205742j. |
Krejcarek et al., Biochem. Biophys. Res. Comm., 77(2), 581-5, (1977). |
Larson et al., J. Nucl. Med., 24, 123-129, (1983). |
Matzku et al., Chemical Abstracts, 99, (1983), #84512y. |
Meares et al., Proc. Natl. Acad. Sci., U.S.A., 73(11), 3803-6, (1976). |
Natali et al., J. Nat. Cancer Inst., 67(3), 591-601, (1981). |
Order et al., Cancer Research, 40, 3001-7, (1980). |
Scheinberg et al., Science, 215, 1511-3, (1982). |
Sfakianakis et al., J. Nucl. Med., 23, 840-50, (1982). |
Sundberg et al., J. Med. Chem., 17(12), 1304-7, (1974). |
Wilson et al., Int. J. Cancer, 28, 293-300, (1981). |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6168946B1 (en) * | 1990-03-22 | 2001-01-02 | Sloan-Kettering Institute For Cancer Research | gp75 as a tumor vaccine for melanoma |
US5744119A (en) * | 1993-05-11 | 1998-04-28 | Sterling Winthrop | Preparation of a radioconjugate formulation |
WO2005000349A2 (en) * | 2003-06-23 | 2005-01-06 | Biolife Science Forschungs- Und Entwicklungsgesellschaft M.B.H. | Passive immune therapy against malignant melanoma |
WO2005000349A3 (en) * | 2003-06-23 | 2005-05-06 | Biolife Science Forschungs Und | Passive immune therapy against malignant melanoma |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5194594A (en) | Modified antibodies | |
US4348376A (en) | Tumor localization and therapy with labeled anti-CEA antibody | |
Hartmann et al. | Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor α-expressing lymphoma utilizing the α-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac | |
US4831122A (en) | Radioimmunotoxins | |
US5004606A (en) | Non-covalent antibody-anthracycline immunocomplexes | |
JPS6270377A (en) | Antibody complex of haptene-modified diagnostic drug and remedy | |
US5130116A (en) | Radiotherapeutic immunoconjugates labeled with iodine-125 | |
AU676162B2 (en) | Method and means for site directed therapy | |
JPH03141230A (en) | Parenteral composition for treating human tumor | |
Fawwaz et al. | Potential of palladium-109-labeled antimelanoma monoclonal antibody for tumor therapy | |
Appelbaum et al. | Antibody-radionuclide conjugates as part of a myeloablative preparative regimen for marrow transplantation | |
Kwok et al. | Optimization of radioimmunotherapy using human malignant melanoma multicell spheroids as a model | |
US20080279772A1 (en) | Methods for detecting pathological sites | |
EP0222360A2 (en) | A method of producing a patient-specific cytotoxic reagent and composition | |
USH819H (en) | Palladium-109 labeled anti-melanoma monoclonal antibodies | |
Anderson et al. | Antibodies labeled with 199Au: Potential of 199Au for radioimmunotherapy | |
Izzo et al. | Localization of an 125I-labeled rat transplantation antibody in tumors carrying the corresponding antigen | |
EP0380542B1 (en) | Method for treating malignancy and autoimmune disorders in humans | |
Lee et al. | Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques | |
Fawwaz et al. | The use of radionuclides for tumor therapy | |
Kinsey et al. | Efficient conjugation of DTPA to an IgM monoclonal antibody in ascites fluid | |
Badger et al. | Biodistribution of p-iodobenzoyl (PIP) labeled antibodies in a murine lymphoma model | |
USH735H (en) | Lead-203 as a label for radioimaging | |
Zhu et al. | Immunoreactivity, stability, pharmacokinetics and biodistribution of a monoclonal antibody to human leukemic B cells after three different methods of radioiodination | |
Otsuji et al. | Biodistribution of monoclonal antibody A7 and its F (ab′) 2 fragment in athymic nude mice bearing human pancreatic carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNITED STATES OF AMERICA AS REPRESENTED BY THE DEP Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:SRIVASTAVA, SURESH C.;FAWWAZ, RASHID A.;FERRONE, SOLDANO;REEL/FRAME:004323/0818;SIGNING DATES FROM 19840426 TO 19840504 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |